Spots Global Cancer Trial Database for older patients
Every month we try and update this database with for older patients cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Improved Function and Quality of Life for Older Patients Receiving Radiotherapy, Part II | NCT03881137 | Cancer Radiotherapy Older Patients | Geriatric asses... | 65 Years - | Sykehuset Innlandet HF | |
| Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia | NCT02844218 | Acute Myeloid L... | Age of patient | 70 Years - 79 Years | Hospices Civils de Lyon | |
| "Geriatric Assessment Adapted" Therapy for Ph- ALL Elderly Patients | NCT00475280 | Leukemia, Lymph... | Geriatric asses... Stem cells auto... | 60 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Lomustine and Intermediate Dose Cytarabine in Older Patients With AML | NCT00480064 | Acute Myeloid L... | Lomustine, inte... | 60 Years - | French Innovative Leukemia Organisation | |
| Improved Function and Quality of Life for Older Patients Receiving Radiotherapy, Part II | NCT03881137 | Cancer Radiotherapy Older Patients | Geriatric asses... | 65 Years - | Sykehuset Innlandet HF | |
| Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT | NCT05084027 | Hematologic Mal... Older Patients Allogeneic Hema... | venetoclax comb... | 50 Years - 80 Years | First Affiliated Hospital of Zhejiang University | |
| Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT01829503 | Acute Myeloid L... | decitabine and ... Supportive Care | 60 Years - | University of Pittsburgh | |
| GEM05 for Patients With Multiple Myeloma More Than 65 Years Old | NCT00443235 | Multiple Myelom... | Melphalan/Predn... Thalidomide/Pre... | 66 Years - | PETHEMA Foundation | |
| ICOPE Program Feasibility in the Management of Myeloma Patients | NCT06247189 | Frailty Multiple Myelom... | ICOPE Monitorin... | 70 Years - | University Hospital, Toulouse | |
| Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT01829503 | Acute Myeloid L... | decitabine and ... Supportive Care | 60 Years - | University of Pittsburgh | |
| Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer | NCT05448547 | Prostate Cancer | Radiotherapy or... initial observa... Hormone therapy | 75 Years - | The Hospital of Vestfold | |
| GEM05 for Patients With Multiple Myeloma More Than 65 Years Old | NCT00443235 | Multiple Myelom... | Melphalan/Predn... Thalidomide/Pre... | 66 Years - | PETHEMA Foundation | |
| Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery | NCT06030804 | Elderly Cancer Surgery Dexmedetomidine Long-Term Survi... | Dexmedetomidine Placebo | 60 Years - | Peking University First Hospital | |
| Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients | NCT04757337 | Advanced Soft-t... Metastatic Soft... | Doxorubicin Cyclophosphamid... | 65 Years - | UNICANCER | |
| Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery | NCT06030804 | Elderly Cancer Surgery Dexmedetomidine Long-Term Survi... | Dexmedetomidine Placebo | 60 Years - | Peking University First Hospital | |
| "Geriatric Assessment Adapted" Therapy for Ph- ALL Elderly Patients | NCT00475280 | Leukemia, Lymph... | Geriatric asses... Stem cells auto... | 60 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| ICOPE Program Feasibility in the Management of Myeloma Patients | NCT06247189 | Frailty Multiple Myelom... | ICOPE Monitorin... | 70 Years - | University Hospital, Toulouse | |
| A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia. | NCT00363025 | Acute Myeloid L... | Two post-remiss... Idarubicin vers... | 65 Years - | Acute Leukemia French Association | |
| Evaluating Harms and Benefits of Endocrine Therapy in Patients ≥70 Years of Age With Lower Risk Breast Cancer | NCT04921137 | Breast Cancer | No endocrine th... Endocrine thera... | 70 Years - | Ottawa Hospital Research Institute | |
| A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia. | NCT00363025 | Acute Myeloid L... | Two post-remiss... Idarubicin vers... | 65 Years - | Acute Leukemia French Association | |
| Evaluating Harms and Benefits of Endocrine Therapy in Patients ≥70 Years of Age With Lower Risk Breast Cancer | NCT04921137 | Breast Cancer | No endocrine th... Endocrine thera... | 70 Years - | Ottawa Hospital Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
